血液がん患者に対するCOVID-19の影響:大流行後期からの洞察
PubMedで要約を見る
まとめ
この要約は機械生成です。血液学的悪性腫瘍の患者は,ワクチン接種を受けた場合でも高いCOVID-19死亡リスクに直面しています. 深刻な感染と死亡率は時間とともに減少したが,これらの患者はSARS-CoV-2の流行期に脆弱のままである.
科学分野
- 血液学
- 感染症
- 腫瘍学
背景
- COVID-19は,血液学的悪性腫瘍の患者の死亡リスクを大幅に高めた.
- 血液学的悪性腫瘍には多発性骨髄腫 (MM),慢性リンパ球性白血病 (CLL),ノンホッジキンリンパ腫 (NHL) が含まれる.
研究 の 目的
- 疫病後期におけるワクチン接種を受けた悪性腫瘍患者におけるCOVID-19の危険因子を特定する.
- この高リスク集団におけるCOVID-19のアウトカムに対するワクチン接種の影響を評価する.
主な方法
- 単一センターでの観察研究が行われました.
- データはパンデミック後期 (2022年−2023年) に収集されました.
- 肝がんとCOVID-19の診断を受けたワクチン接種患者に焦点を当てました.
主要な成果
- 85人のCOVID-19症例が分析され,MM,CLL,NHLが一般的であった.
- 高いワクチン接種率 (97. 6%) にもかかわらず,23. 5%が重症/危篤な病気を経験した.
- 総死亡率と30日死亡率はそれぞれ22. 4%と11. 8%であった.
- 死亡率は時間が経つにつれ減少したが,重大な感染症例では減少しなかった.
結論
- 血液学的悪性腫瘍の患者は,SARS-CoV-2感染による持続的な高リスクに直面しています.
- 慢性的な感染と死亡率が減ったとしても,この集団は流行期に脆弱のままです.
関連する概念動画
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

